Filter your search
Drug Discovery Market ReportsX
Kalorama Information market research studies have the data you need on the drug discovery market opportunity, providing analysis, projections, and information on market direction. Drug discovery operations can prove time-consuming and difficult, and may come at a high economic cost, which has driven outsourcing in this field. Kalorama explores an important segment, the contract research organization segment, looking in detail at an approach that is helping to shape the drug discovery market today.
- $3,995.00 – $7,590.00This Kalorama Information report – Clinical Nutrition – focuses on three primary segments of essential medical nutrition: Infant Nutrition: (Milk-based, Soy-based, Special Needs such as Chronic Reflux or Gastrointestinal Discomfort) Enteral Nutrition (Standard and Fiber-containing Elemental and Semi-elemental, Specialized for Chronically Ill Patients) Parenteral Nutrition For each category, the report provides revenue data and forecasts […]February 1, 2009$995.00 – $7,000.00This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing of prescription drugs and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. A major factor driving the upward trend in the number of manufacturing projects being outsourced is that […]January 1, 2009$3,500.00 – $7,000.00Driven by mounting market pressures, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry. Kalorama Information’s Outsourcing in Drug Development is the third edition of this […]October 1, 2008$1,500.00 – $4,995.00Alzheimer’s Disease is the most common cause of dementia, constituting 60% to 70% of all cases, and the risk with the disease doubles every 5 years after age 65. Incidence of the disease is increasing, and the resulting attention given to Alzheimer’s Disease has encouraged development of new treatments. There is an opportunity for pharmaceutical […]August 1, 2008$3,500.00 – $7,000.002008 has seen no decrease in the opportunities available for outsourcing drug discovery, for a number of reasons. New technologies increase the number of targets and accelerate the identification of active compounds. There is increasing pressure to develop new lead compounds due to the near-term loss of patent protection for many drug product. And there […]May 1, 2008$995.00 – $7,000.00Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United […]January 1, 2008$995.00 – $7,990.00Kalorama’s 2nd edition of The World Cardiovascular Drugs Market, in its 2nd edition, will steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments. Analyst Mary Ann Crandall considers both the exisiting products […]December 1, 2007$1,500.00 – $7,000.00Offshoring of clinical trials is increasing as companies in the U.S. are finding challenges in clinical trial research ranging from cost, patient recruitment, patient compliance during participation, qualified professionals, new clinical trial patients, and other problems. This provides an opportunity for BRIC countries and other developing regions to grab a piece of the clinical trial […]November 1, 2007$995.00 – $1,990.00The importance, danger and costs of tuberculosis in the 21st century cannot be understated or underestimated. Though nearly extinct in the 20th century, over 1.6 billion people worldwide suffer from tuberculosis, and it is now presenting a major crisis in public health circles. As illustrated by Kenneth G. Krul, Phd., in Kalorama Information’s Global Tuberculosis […]June 1, 2007$1,990.00 – $6,990.00Toxicity is a crucial parameter that is measured throughout the drug development process. Toxic side-effects are one of the most common reasons drug candidates fail. Toxicity can be a factor of dose, the form in which the drug is administered, and the time of exposure before elimination. Patient responses also differ widely, depending on their […]June 1, 2007